Adverse effects in women: implications for drug development and regulatory policies
Ameeta Parekh(United States Food and Drug Administration), Douglas C. Throckmorton(United States Food and Drug Administration), Emmanuel O. Fadiran(United States Food and Drug Administration), Kathleen Uhl(Center for Drug Evaluation and Research)
Cited by 115
Related Papers
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products
|Kidney International|1995|174
Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony-stimulating factor and interferon gamma.
|The Journal of Experimental Medicine|1995|172